PTPRC and neoplasm: In contrast, SX-682 blockade of CXCR1/2 in B16F10 tumors resulted in increased CD45+ immune cells, increased intratumoral CD8+T cells and CD69+CD8+ T cells, increased CD44+ CD4+ T cells and CD62L+ CD4+ T cells, and reduced CD11b+CD45+ cells, Ly6G+CD11b+ and CD14+Ly6G+ myeloid cells (Figure 3C). The combination of SX682 and palbociclib inhibited B16F10 melanoma tumor growth, increased the percentage of CD45+ cells, CD3+CD8+ T-cells, CD4+CD44+ T cells, and CD62L+CD4+ T cells.